Cargando…

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3

Hyperactivation of phosphatidylinositol-3 kinase (PI3K) can occur as a result of somatic mutations in PIK3CA, the gene encoding the p110α subunit of PI3K. The HER2 oncogene is amplified in 25% of all breast cancers and some of these tumors also harbor PIK3CA mutations. We examined mechanisms by whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakrabarty, Anindita, Rexer, Brent N., Wang, Shizhen Emily, Cook, Rebecca S., Engelman, Jeffrey A., Arteaga, Carlos, L.
Formato:	Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945381/ https://www.ncbi.nlm.nih.gov/pubmed/20581867 http://dx.doi.org/10.1038/onc.2010.257

Ejemplares similares

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2004)

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
por: Rexer, Brent N, et al.
Publicado: (2014)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
por: Miller, Todd W, et al.
Publicado: (2011)

Optical imaging of metabolism in HER2 overexpressing breast cancer cells
por: Walsh, Alex, et al.
Publicado: (2011)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
por: Kang, Jeffrey C, et al.
Publicado: (2014)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Androgen receptor transcriptional activity is required for heregulin-1β–mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase
por: Jathal, Maitreyee K., et al.
Publicado: (2023)

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
por: Al-Akhrass, Hussein, et al.
Publicado: (2021)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
por: Momeny, Majid, et al.
Publicado: (2015)

PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015)

A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor
por: Hinow, Peter, et al.
Publicado: (2007)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
por: Rexer, Brent N., et al.
Publicado: (2011)

The phosphatidylinositol-3 kinase/mTOR pathway: new agents
por: Arteaga, CL
Publicado: (2011)

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy
por: Wang, Shizhen Emily
Publicado: (2011)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K
por: Yueh, Alexander E., et al.
Publicado: (2016)

Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers
por: Young, Christian D., et al.
Publicado: (2015)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

MicroRNA and HER2-overexpressing Cancer
por: Wang, Shizhen Emily, et al.
Publicado: (2013)

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
por: Gkeka, Paraskevi, et al.
Publicado: (2014)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation
por: Pan, Min-Hsiung, et al.
Publicado: (2011)

HER-3: hub for escape mechanisms
por: Capone, Emily, et al.
Publicado: (2015)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vl02vtimlptv285orcv885enoi